Q2 2021 Results - Reimagining Medicine
Participants
Financial performance
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
References
Innovation: Pipeline overview
Innovation: Clinical trials
CRM
IHD
Neuroscience
Oncology
Ophthalmology
Respiratory
Sandoz Biopharmaceuticals
Global Health
Abbreviations
JakaviⓇ
-
JAK1/2 inhibitor
Study
Indication
Phase
Patients
NCT04097821 ADORE (CINC424H12201)
Myelofibrosis
Phase 1/2
130
Primary Outcome
Measures
Arms Intervention
Incidence of dose limiting toxicities within the first 2 cycles
Response rate at the end of cycle 6
Ruxolitinib
Ruxolitinib+Siremadlin
Ruxolitinib+Crizanlizumab
Ruxolitinib+MBG453
Ruxolitinib+LTT462
Ruxolitinib+NIS793
Patients with Myelofibrosis (MF)
Target Patients
Read-out Milesstone(s)
Publication
2024
TBD
102 Investor Relations | Q2 2021 Results
NOVARTIS | Reimagining MedicineView entire presentation